Figure 8. Pharmacologic stabilization of IFNAR1 disrupts immune privileged niche and elicits a therapeutic effect against tumors.

(A) Immunoblot analysis of phosphorylation and levels of p38α and PKD2 kinases in cultured MC38 cells and MC38 tumors.

(B) Levels of cell surface IFNAR1 on tumor infiltrating CD3⁺CD8⁺ cells isolated from MC38 tumors grown in WT or Ifnar1-null mice treated with kinase inhibitors as indicated. Representative FACS and quantification are shown.

(C) Frequency of CD8⁺ T cells (% of CD45⁺ cells) isolated from MC38 tumors grown in WT or Ifnar1-null mice treated with kinase inhibitors as indicated.

(D) Quantification of results shown in panel C.

(E) Anti-tumor effect of SD-208 and LY2228820 administered to Ifnar1^−/− and WT mice bearing MC38 tumors as described in Methods.

Data are shown as Mean±SEM (n=5 from each of 3 independent experiments).

See also Figure S8